ATRA vs. PLX, CRIS, ALVR, CVM, SGMO, ATHA, CGTX, PASG, VIGL, and GRTS
Should you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Protalix BioTherapeutics (PLX), Curis (CRIS), AlloVir (ALVR), CEL-SCI (CVM), Sangamo Therapeutics (SGMO), Athira Pharma (ATHA), Cognition Therapeutics (CGTX), Passage Bio (PASG), Vigil Neuroscience (VIGL), and Gritstone bio (GRTS). These companies are all part of the "biological products, except diagnostic" industry.
Protalix BioTherapeutics (NYSE:PLX) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk.
Atara Biotherapeutics received 424 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. Likewise, 67.67% of users gave Atara Biotherapeutics an outperform vote while only 62.50% of users gave Protalix BioTherapeutics an outperform vote.
Protalix BioTherapeutics currently has a consensus target price of $10.00, indicating a potential upside of 777.19%. Atara Biotherapeutics has a consensus target price of $28.00, indicating a potential upside of 4,079.10%. Given Protalix BioTherapeutics' higher possible upside, analysts plainly believe Atara Biotherapeutics is more favorable than Protalix BioTherapeutics.
16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 5.0% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 4.5% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Atara Biotherapeutics had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 2 mentions for Atara Biotherapeutics and 1 mentions for Protalix BioTherapeutics. Atara Biotherapeutics' average media sentiment score of 0.84 beat Protalix BioTherapeutics' score of 0.67 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.
Protalix BioTherapeutics has a net margin of 12.69% compared to Protalix BioTherapeutics' net margin of -3,220.88%. Atara Biotherapeutics' return on equity of 29.73% beat Protalix BioTherapeutics' return on equity.
Protalix BioTherapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.
Protalix BioTherapeutics has higher revenue and earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Protalix BioTherapeutics beats Atara Biotherapeutics on 12 of the 18 factors compared between the two stocks.
Get Atara Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atara Biotherapeutics Competitors List
Related Companies and Tools
